

COVER LETTER

We are submitting the manuscript “Virtual screening ligand-structure based from 16- (N, N-diisobutylaminomethyl)-6 α -hydroxyivouacapan-7 β , 17 β -lactone compound with potential anti-cancer activity Prostate” for possible publication in the Journal of the Serbian Chemical Society.

The Prostate cancer is one of the leading causes of disease and death on the planet. The 16-(N, N-diisobutylaminomethyl)-6 α -hydroxyivouacapan-7 β ,17 β -lactone (N,N-DHL) compound with prostatic anti-cancer activity had probable bioactive pose via semi-empirical method (PM3) and refined with base set 6-31+G(d, p) calculated in the DFT method with theory level B3LYP. Our results showed that of 238.922, in the final selection were only eight with good potential anti-cancer activity Prostate.

The authors guarantee that the manuscript submitted to the Journal for review is original, was written by the stated authors and has not been published elsewhere; is currently not being considered for publication by any other journal and will not be submitted for such a review while under review by the Journal; the manuscript contains no libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any other person or entity. We declare that there are no conflicts of interest. Moreover, we are aware that, if the manuscript is accepted for publication, copyright now belong to the Journal of the Serbian Chemical Society.

We suggest for evaluate the manuscript the following reviewers:

- Joaquin Maria Campos Rosa
E-mail: jmcampos@ugr.es.
- Irlon Ferreira Maciel
E-mail: irlon.ferreira@gmail.com
- Rosivaldo Borges dos Santos
E-mail: lqfmed@gmail.com

Belem-PA, January 29, 2018, Brazil.

Yours faithfully,

RAÍ CAMPOS SILVA, JOÃO GABRIEL CURTOLO POIANI, RYAN DA SILVA RAMOS, JOSIVAN DA SILVA COSTA, CARLOS HENRIQUE TOMICH PAULA DA SILVA, DAVI DO SOCORRO BARROS BRASIL AND CLEYDSON BRENO RODRIGUES DOS SANTOS.